Luciano Consuegra-Sánchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luciano Consuegra-Sánchez has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Antonio Melgarejo-Moreno
Hospital Universitario Santa Lucía de Cartagena, Murcia, Spain
7 shared publicationsLeticia Jaulent-Huertas
Hospital Universitario Santa Lucía de Cartagena, Murcia, Spain
7 shared publicationsMarta Vicente-Gilabert
Hospital Clínico Universitario Virgen de la Arrixaca de Murcia, Murcia, Spain
7 shared publicationsGermán Escudero-García
Servicio de Medicina Intensiva, Hospital Universitario de Santa Lucía, Cartagena, Murcia, Spain
5 shared publicationsNuria Alonso-Fernández
Servicio de Medicina Intensiva, Hospital Universitario de Santa Lucía, Cartagena, Murcia, Spain
5 shared publicationsÁngela Díaz-Pastor
Hospital Universitario Santa Lucía de Cartagena, Murcia, Spain
5 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 12 (1) , e002917
Causes of death in NBA players: a competing risks analysis
Objective: To analyse the causes of death and factors associated with mortality among NBA players using verifiable open-source data and a time-to-event approach accounting for competing risks. Methods: This retrospective cohort study included all 4374 former and active NBA players from 1946 to July 2019. Players who exclusively played in the American Basketball Association were excluded. The main exposure was participation in the NBA. The primary outcome was cause-specific death, categorised into: neoplasms, cardiovascular diseases, external causes and idiopathic. Ethnicity and height were assessed as predictors using cause-specific adjusted Cox models. Results: By July 2019, 864 players (19.8%) had died, 855 of them identified as African ancestry or European ancestry. Among these, 47.6% of deaths were idiopathic, 20.1% due to neoplasms, 17.6% due to cardiovascular diseases, 8.1% due to external causes and 6.5% due to other specified causes. From age 60 years onwards, neoplasms and cardiovascular diseases were the leading causes of death. At age 85 years, the estimated cardiovascular disease-related mortality was higher in African ancestry players (27%) than in European ancestry players (20%). African ancestry ethnicity was associated with increased risk of cardiovascular death (adjusted HR 1.32; 95% CI 1.06 to 1.65), and height was positively associated with mortality from both neoplasms and cardiovascular diseases. Conclusions: In this cohort of NBA players, neoplasms and cardiovascular diseases emerged as the primary causes of death, particularly among African ancestry athletes and taller individuals. These findings underscore the need to view the long-term health of elite athletes as a public health priority.
- 30 January 2026
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 12 (1) , e002917
Open AccessCauses of death in NBA players: a competing risks analysis
Objective: To analyse the causes of death and factors associated with mortality among NBA players using verifiable open-source data and a time-to-event approach accounting for competing risks. Methods: This retrospective cohort study included all 4374 former and active NBA players from 1946 to July 2019. Players who exclusively played in the American Basketball Association were excluded. The main exposure was participation in the NBA. The primary outcome was cause-specific death, categorised into: neoplasms, cardiovascular diseases, external causes and idiopathic. Ethnicity and height were assessed as predictors using cause-specific adjusted Cox models. Results: By July 2019, 864 players (19.8%) had died, 855 of them identified as African ancestry or European ancestry. Among these, 47.6% of deaths were idiopathic, 20.1% due to neoplasms, 17.6% due to cardiovascular diseases, 8.1% due to external causes and 6.5% due to other specified causes. From age 60 years onwards, neoplasms and cardiovascular diseases were the leading causes of death. At age 85 years, the estimated cardiovascular disease-related mortality was higher in African ancestry players (27%) than in European ancestry players (20%). African ancestry ethnicity was associated with increased risk of cardiovascular death (adjusted HR 1.32; 95% CI 1.06 to 1.65), and height was positively associated with mortality from both neoplasms and cardiovascular diseases. Conclusions: In this cohort of NBA players, neoplasms and cardiovascular diseases emerged as the primary causes of death, particularly among African ancestry athletes and taller individuals. These findings underscore the need to view the long-term health of elite athletes as a public health priority.
- 9 October 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 395, 131427
Modulating the phenotypic transition of vascular smooth muscle cells via LKB1, a new pharmacologic target to strike atherosclerosis?
- 9 October 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 395, 131427
Modulating the phenotypic transition of vascular smooth muscle cells via LKB1, a new pharmacologic target to strike atherosclerosis?
- Open Access
- 28 August 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 111, 211-218
Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients
- 28 August 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 111, 211-218
Open AccessCirculating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients
- 16 July 2021
- Published by Instituto Mexicano del Seguro Social in REC: Interventional Cardiology (English Edition)
- Vol. 2 (4) , 306-307
ISCHEMIA trial: a win for the optimal medical therapy in the management of stable coronary artery disease?
Revista Española de Cardiología: Interventional Cardiology
- 16 July 2021
- Published by Instituto Mexicano del Seguro Social in REC: Interventional Cardiology (English Edition)
- Vol. 2 (4) , 306-307
ISCHEMIA trial: a win for the optimal medical therapy in the management of stable coronary artery disease?
Revista Española de Cardiología: Interventional Cardiology
- 1 January 2021
- Published by Elsevier in REC: CardioClinics
- Vol. 56, 1-2
Introducción: novedades del año 2020
- 1 January 2021
- Published by Elsevier in REC: CardioClinics
- Vol. 56, 1-2
Introducción: novedades del año 2020
- Open Access
- 17 October 2018
- Published by Wiley in BioMed Research International
- Vol. 2018, 1-9
Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge
Background. Anticoagulation with vitamin K antagonists continues to be a challenging task given the difficulty of achieving a correct time in therapeutic range (TTR). The SAMeTT2R2 score has been proposed to identify patients that will be good responders. In this study we aimed to analyse clinical and genetic factors involved in a correct level of anticoagulation in patients with atrial fibrillation and thereby potentially improve the diagnostic performance of SAMeTT2R2 score. Methods. We prospectively included 212 consecutive patients with nonvalvular atrial fibrillation under treatment with acenocoumarol for at least 6 months that were attended in a cardiology outpatient clinic and were categorized as adherent to medication. We carried out a multivariate regression analysis to detect the independent predictive factors of good control. In all patients VKORC1, CYP2C92, CYP2C93, and MIR133A2 genotyping was performed. Results. A total of 128 (60.4%) patients presented TTR <70% (average TTR = 63.2). We identified body mass index (OR 0.94, 95%CI 0.89-0.99, p=0.032) and regular vitamin K intake (OR 0.53, 95%CI 0.28-0.99, p= 0.046) as independent predictors of poor anticoagulation control. The discriminatory power of a clinical-genetic model derived from our cohort was significantly better compared to the SAMeTT2R2 score (C-statistic 0.658 versus 0.524, p<0.001). Conclusions. In our study the SAMeTT2R2 score revealed a poor ability in the prediction of TTR. Besides SAMeTT2R2, body mass index and possibly vitamin K intake should be taken into account when deciding the optimal anticoagulation strategy. The information provided by the identified genotypes was marginal.- 17 October 2018
- Published by Wiley in BioMed Research International
- Vol. 2018, 1-9
Open AccessLow Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge
Background. Anticoagulation with vitamin K antagonists continues to be a challenging task given the difficulty of achieving a correct time in therapeutic range (TTR). The SAMeTT2R2 score has been proposed to identify patients that will be good responders. In this study we aimed to analyse clinical and genetic factors involved in a correct level of anticoagulation in patients with atrial fibrillation and thereby potentially improve the diagnostic performance of SAMeTT2R2 score. Methods. We prospectively included 212 consecutive patients with nonvalvular atrial fibrillation under treatment with acenocoumarol for at least 6 months that were attended in a cardiology outpatient clinic and were categorized as adherent to medication. We carried out a multivariate regression analysis to detect the independent predictive factors of good control. In all patients VKORC1, CYP2C92, CYP2C93, and MIR133A2 genotyping was performed. Results. A total of 128 (60.4%) patients presented TTR <70% (average TTR = 63.2). We identified body mass index (OR 0.94, 95%CI 0.89-0.99, p=0.032) and regular vitamin K intake (OR 0.53, 95%CI 0.28-0.99, p= 0.046) as independent predictors of poor anticoagulation control. The discriminatory power of a clinical-genetic model derived from our cohort was significantly better compared to the SAMeTT2R2 score (C-statistic 0.658 versus 0.524, p<0.001). Conclusions. In our study the SAMeTT2R2 score revealed a poor ability in the prediction of TTR. Besides SAMeTT2R2, body mass index and possibly vitamin K intake should be taken into account when deciding the optimal anticoagulation strategy. The information provided by the identified genotypes was marginal. - 10 September 2018
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 72 (7) , 587-588
Medición de la satisfacción del paciente en un servicio de cardiología mediante mapas asociativos: un nuevo método
- 10 September 2018
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 72 (7) , 587-588
Medición de la satisfacción del paciente en un servicio de cardiología mediante mapas asociativos: un nuevo método
- 20 July 2018
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 72 (7) , 587-588
Measuring Patient Satisfaction in a Cardiology Service Using Associative Maps. A New Method
- 20 July 2018
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 72 (7) , 587-588
Measuring Patient Satisfaction in a Cardiology Service Using Associative Maps. A New Method
- 1 March 2018
- Published by Elsevier in Medicina Intensiva (English Edition)
- Vol. 42 (2) , 73-81
Hormona paratiroidea, calcidiol, calcitriol y riesgo de eventos adversos en pacientes con síndrome coronario agudo
- 1 March 2018
- Published by Elsevier in Medicina Intensiva (English Edition)
- Vol. 42 (2) , 73-81
Hormona paratiroidea, calcidiol, calcitriol y riesgo de eventos adversos en pacientes con síndrome coronario agudo